They found that compared with single component or dual drug combination, ATI can increase the ubiquitination/degradation of promyelocytic leukemia (PML)-retinoic acid receptor α (RARα) oncoprotein, enhance the reprogramming of myeloid differentiation regulators, and enhance G1/G0 block in APL cells by striking multiple targets. This evidence concerns the gene RARA and acute promyelocytic leukemia.